



Meditech Center
L.J. Zielstraweg 1
9713 GX Groningen
The Netherlands

PRESS RELEASE

Groningen, the Netherlands, May 3, 2012

Mucosis announces publication of preclinical data demonstrating superior protection by mucosally administered Mimopath[®]-based influenza vaccines

Mimopath[®]-based influenza vaccine protects against both homologous and heterologous challenge

Dutch biotechnology company Mucosis B.V. today announced the publication in the peer-reviewed journal *Vaccine* of preclinical data showing that FluGEM[®] provides superior cross-protection against influenza virus. FluGEM[®] is a new Mimopath[®]-based mucosal influenza vaccine that can be administered through simple droplets in the nose.

According to the report, FluGEM[®], a vaccine based on traditional inactivated influenza antigens formulated with bacterium-like particles (BLPs), provided full protection in mice against both homologous and heterologous influenza infection. Moreover, the results show more than 300-fold lower viral titers in the lungs when compared to conventional influenza vaccination. Reduction of viral lung titers more efficiently protects against disease, but may also result in decreased viral shedding, thereby increasing herd immunity. The data demonstrate that Mucosis' unique Mimopath[®] technology can be used to develop needle-free vaccines that are more efficacious than conventional vaccines.

Dr. Kees Leenhouts, CSO of Mucosis: "We are extremely pleased with the results of this study. It is a pivotal step in the further validation of our platform technology for the development of novel and improved vaccines to protect against infectious diseases."

Mucosis will continue to develop the FluGEM[®] vaccine candidate in cooperation with corporate, governmental and non-governmental partners. The company's lead vaccine candidate based on the same Mimopath[®] technology, called SynGEM[™], is designed to prevent infections with Respiratory Syncytial Virus (RSV), which affect over 60 million people worldwide ranging from the very young to the elderly with more than one million hospitalizations annually. An RSV vaccine does not yet exist.

For further information please contact:

Thomas Johnston
Chief Business Officer Mucosis
+31 (50) 8200050
tom.johnston@mucosis.com
www.mucosis.com

About Mucosis

Mucosis B.V. is a clinical-stage Dutch biotechnology company with a proprietary platform technology, Mimopath[®], on which it develops mucosal vaccines with improved efficacy. Mucosis's lead products are SynGEM[™], a vaccine to prevent RSV viral infection, PneuGEM[®], a vaccine to prevent diseases caused by pneumococcal bacteria and FluGEM[®], a vaccine to prevent influenza. Mimopath[®]-based vaccines can be administered needle-free in the nose and mouth, evoking a more natural immune response with a broader base of protection.

About Mimopath[®] technology

The Mimopath[®] technology is based on *Lactococcus lactis*, a safe bacterium commonly used in the food industry. Mucosis has developed a robust technique to formulate the *L. lactis* bacteria into non-living bacterium-like particles (BLPs) that can be loaded with antigens from viral, bacterial, parasitic or tumor origin. The antigen-covered BLPs form a vaccine that can be delivered into the nose or mouth, without the need for a needle. These vaccines raise protective immunity by activation of both the innate and the adaptive immune system.